Past issues are only available to subscribers. If you are not a member, click here to join.

Issue 9 - Mar. 1, 2019
Issue 8 - Feb. 22, 2019
  • NCI invites scientists to step up competition for $173 million set-aside for commercialization

    NCI would like you to know that it has a pot of money for commercialization projects—please apply.

    Together, the institute’s Small Business Innovation Research and Small Business Technology Transfer programs are giving out $173 million in fiscal 2019. At NIH, these programs gave out $1.145 billion.

  • Conversation with The Cancer Letter

    Caryn Lerman on leading USC Norris: Team science is where breakthroughs emerge

    Caryn Lerman was named director of USC Norris Comprehensive Cancer Center.

    When she reports to work at USC on March 15, Lerman will be the only behavioral scientist to lead an NCI-designated cancer center. She also will hold the position of professor of psychiatry and the behavioral sciences at the Keck School of Medicine of USC.

  • In Brief

    • NCI’s Rosenberg to receive Szent-Györgyi prize
    • Vale named executive director of HHMI Janelia Research Campus
    • Baylor consolidates cancer center clinics on new McNair Campus
    • Merck to acquire Immune Design
    • Doubrava joins Fox Chase
  • Funding Opportunities

    ASCO invites applications for research based on data from CancerLinQ Discovery

    The American Society of Clinical Oncology is inviting applications for research grants for projects that use data from CancerLinQ Discovery, an offering of ASCO’s CancerLinQ initiative, as a source.

  • TCCL Logo

  • Clinical Roundup

    • Guidelines recommend genetic testing for all people with breast cancer
    • Keytruda + Inlyta reduced risk of death by nearly half compared to sunitinib in RCC
    • OS and PFS for Keytruda in hepatocellular carcinoma did not meet statistical significance
    • Merck expands immuno-oncology program with three phase III trials in prostate cancer
    • Opdivo + Yervoy shows response in pre-treated patients with prostate cancer
    • Janssen announces preliminary results from phase II GALAHAD in prostate cancer
    • Roswell Park researchers identify protein that contributes to racial disparities in prostate cancer
    • AVEO Oncology announces TIVO-3 trial topline results 
    • SCLC may respond to combination of immunotherapy and DNA damage repair inhibitors
    • Study finds melanoma brain metastases immunosuppressive with treatment-resistant metabolism
    • Dasatinib enhances response to checkpoint inhibitors, study finds
    • Integrating heart disease and cancer care could reduce overall health care costs
    • CASSINI Trial publishes data on preventing blood clots in cancer patients
  • Drugs & Targets

    • FDA approves Keytruda for adjuvant treatment of melanoma
    • FDA accepts IND for TR1801-ADC, an ADC targeting cMet positive solid tumors
    • FDA grants priority review to Merck’s sBLA for Keytruda monotherapy in SCLC
    • FDA publishes revised draft guidance for investigational tobacco products
Issue 7 - Feb. 15, 2019
  • Guest Editorial

    Making the case to double NIH

    The decision to double the budget of the National Institutes of Health should be easy, because it will save lives and save our economy simultaneously. The case for NIH is overwhelming, and there is broad bipartisan congressional support. So why is it so challenging?

  • NCI Director’s Report

    Sharpless: Please stay in oncology, don’t stop sending good research ideas to NCI

    The mathematical concepts underlying the challenge NCI is facing today aren’t difficult to grasp. In fact, a 14-year-old in an algebra class should be able to get it, NCI Director Ned Sharpless said to the National Cancer Advisory Board Feb. 12.

  • In Brief

    • Caryn Lerman named director at USC Norris Comprehensive Cancer Center
    • St. Baldrick’s and ACS form partnership focused on pediatric cancers
    • Report calls on US to accelerate the elimination of cervical cancer worldwide
  • TCCL Logo

  • Clinical Roundup

    • Keytruda + Inlyta improves OS, PFS and ORR vs. Sunitinib in RCC
    • Immunotherapy appears better than chemotherapy for skin cancer
    • Group of lymph nodes to determine prognosis for mesothelioma
    • Phase III ARCHES trial shows Xtandi improved PFS in prostate cancer
    • Opdivo + Yervoy shows continued survival benefit in RCC
    • Immunotherapy effective in recurrent glioblastoma
    • Black-white cancer mortality gap nearly eliminated in some age groups
    • Report calls on US to accelerate the elimination of cervical cancer worldwide
  • Drugs & Targets

    • European Commission approves Sprycel + chemo for pediatric
    • FDA grants Priority Review for Keytruda in head and neck squamous cell carcinoma
    • FDA accepts sBLA and grants Priority Review for Bavencio + Inlyta in RCC